Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2018-01-26 AccNo: 0000947871-18-000055 Size: 145 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2017-12-12 AccNo: 0001104659-17-072945 Size: 131 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2017-11-29,Chief Commercial Officer,Lavino Francesco Maria ,买入,1569普通股, $6.29
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-11-09 AccNo: 0001104659-17-067391 Size: 4 MB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 8-K - Current report Filed: 2017-11-09 AccNo: 0001104659-17-067209 Size: 235 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 8-K - Current report Filed: 2017-11-07 AccNo: 0001104659-17-066475 Size: 9 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-10-10 AccNo: 0001104659-17-061579 Size: 94 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2017-09-22,CEO,Broom Colin MD ,买入,2588普通股, $8.35
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2017-09-22,CFO,Sender Gary ,买入,2000普通股, $8.21
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 8-K - Current report Filed: 2017-09-20 AccNo: 0001104659-17-058089 Size: 378 KBItem 1.01: Entry into a Material Definitive AgreementItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接